Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05784974 | Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer | not yet recruiting | Phase 2 | 37 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05784142 | Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)(CHIC) | active not recruiting | Phase 2 | 55 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05778097 | Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)(ARES) | not yet recruiting | Phase 2 | 103 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05638594 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | recruiting | Phase 2 | 236 | Shengjing HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05286957 | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC(Seagull) | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05732051 | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients(NARNIA) | recruiting | Phase 2 | 60 | University Hospital, AkershusOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05766410 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC(ORACLE-RIPA) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05595603 | Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage | recruiting | Phase 2 | 153 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05736965 | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia(SAV) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05736978 | Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results(AVS) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05762900 | Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients(UNIQUE) | recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05536102 | The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) | recruiting | Phase 2 | 38 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | recruiting | Phase 2 | 40 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05757336 | Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer | recruiting | Phase 2 | 50 | Lu Wang, MD, PhDOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04959903 | Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT | recruiting | Phase 1 / Phase 2 | 36 | Smart Immune SASINDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05753566 | Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 96 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05136326 | Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer(CATARTIC) | recruiting | Phase 2 | 21 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05151588 | Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma | not yet recruiting | Phase 2 | 30 | Dr. Victor H.F. LeeOTHER | 0 | Feb 28, 2023 | clinicaltrials |
| NCT05747716 | SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC | not yet recruiting | Phase 2 | 44 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04499573 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL | active not recruiting | Phase 1 / Phase 2 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04501523 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC(Apollo) | recruiting | Phase 2 | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04813705 | 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 93 | Taizhou HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05725200 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05732662 | SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC | not yet recruiting | Phase 2 | 25 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT05717582 | Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment(CHAMPION) | not yet recruiting | Phase 2 | 47 | Fudan UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04014530 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study(ATAPEMBRO) | recruiting | Phase 1 / Phase 2 | 47 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04304209 | Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 195 | Sun Yat-sen UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05210270 | HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy(HYACINCT) | not yet recruiting | Phase 1 / Phase 2 | 55 | University of Santo Tomas Hospital, PhilippinesOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction(FASTIMMUNE) | not yet recruiting | Phase 2 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05692674 | A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction | recruiting | Phase 2 | 67 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05686434 | Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) | recruiting | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05682755 | Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | recruiting | Phase 1 / Phase 2 | 77 | Sichuan UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT04833387 | PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer | active not recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05679583 | Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05252078 | Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients(ALTER-E005) | recruiting | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05648487 | HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis | not yet recruiting | Phase 2 | 46 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Dec 16, 2022 | clinicaltrials |
| NCT05651672 | Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations | recruiting | Phase 2 | 100 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652192 | SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC | recruiting | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05594797 | Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM | recruiting | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05300945 | HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 200 | Zhixin CaoOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT05000892 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | recruiting | Phase 2 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05628922 | Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT | recruiting | Phase 2 | 198 | Fudan UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 65 | Molly GalloglyOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05618821 | Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer | recruiting | Phase 2 | 68 | Fujian Medical UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 27, 2023source: clinicaltrials